Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus

Trial Profile

Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Canagliflozin (Primary) ; Dapagliflozin (Primary) ; Empagliflozin (Primary) ; CD26 antigen inhibitors; Glucagon-like peptide 1 agonist; Insulin; Sulfonylureas; Thiazolidinediones
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms EASEL
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 17 Nov 2017 Primary endpoint has been met. (Incidence Rate of the Composite of All-cause Mortality (ACM) or Hospitalization for Heart Failure (HF)), according to a Janssen Pharmaceuticals media release.
    • 17 Nov 2017 Results of retrospective analysis presented in a Janssen Pharmaceuticals media release.
    • 17 Nov 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top